Meningococcal Disease

Tropical Infectious Diseases

Volumn , Issue , 2011, Pages 174-183

  De Souza, Alexandre Leite ^a   Van De Beek, Diederik ^b   Scheld, W Michael ^c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885153567     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7020-3935-5.00024-0     Document Type: Chapter

References (139)

1. de Souza AL, Seguro AC Two centuries of meningococcal infection: from Vieusseux to the cellular and molecular basis of disease. J Med Microbiol 2008, 57:1313.
2. Scheld WM, Koedel U, Nathan B, et al. Pathophysiology of bacterial meningitis: mechanism(s) of neuronal injury. J Infect Dis 2002, 186:S225.
3. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004, 39:1267.
4. Roberts L An ill wind, bringing meningitis. Science 2008, 320:1710.
5. Howitz M, Lambertsen L, Simonsen JB, et al. Morbidity, mortality and spatial distribution of meningococcal disease, 1974-2007. Epidemiol Infect 2009, 137(11):1631. published online.
6. Darton T, Guiver M, Naylor S, et al. Severity of meningococcal disease associated with genomic bacterial load. Clin Infect Dis 2009, 48:587.
7. Brouwer MC, de Gans J, Heckenberg SG, et al. Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis. Lancet Infect Dis 2009, 9:31.
8. Heckenberg SG, de Gans J, Brouwer MC, et al. Clinical features, outcome, and meningococcal genotype in 258 adults with meningococcal meningitis: a prospective cohort study. Medicine 2008, 87:185.
9. North E Concerning the epidemic of spotted fever in New England. Rev Infect Dis 1980, 2:811.
10. Roos KL, Tunkel AR, Scheld WM Acute bacterial meningitis in children and adults. Infections of the Central Nervous System 1997, 335. Lippincott-Raven, Philadelphia. 2nd edn. W.M. Scheld, R.J. Whitley, D.T. Durack (Eds.).
11. Scheld WM, Mandell GL Sulfonamides and meningitis. JAMA 1984, 251:791.
12. Apicella MA Neisseria meningitidis. Principles and Practice of Infectious Diseases 1995, 1896. Churchill Livingstone, New York. 4th edn. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
13. Frasch CE, Zollinger WD, Poolman JT Proposed schema for identification of serotypes of Neisseria meningitidis. The Pathogenic Neisseria 1985, 519. American Society for Microbiology, Washington, DC. G.K. Schoolnik (Ed.).
14. Scheld WM Meningococcal diseases. Tropical and Geographical Medicine 1990, 798. McGraw-Hill, New York. 2nd edn. K.S. Warren, A.A.F. Mahmoud (Eds.).
15. Caugant DA, Mocca IF, Frasch CE, et al. Genetic structure of Neisseria meningitidis populations in relation to serogroup, serotype, and outer membrane protein pattern. J Bacteriol 1987, 169:2781.
16. Maiden MC, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 1998, 95:3140.
17. Feavers IM ABC of meningococcal diversity. Nature 2000, 404:451.
18. Rytkonen A, Albiger B, Hansson-Palo P, et al. Neisseria meningitidis undergoes PilC phase variation and PilE sequence variation during invasive disease. J Infect Dis 2004, 189:402.
19. Sun YH, Bakshi S, Chalmers R, et al. Functional genomics of Neisseria meningitidis pathogenesis. Nat Med 2000, 6:1269.
20. Parkhill J, Achtman M, James KD, et al. Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature 2000, 404:502.
21. Tettelin H, Saunders NJ, Heidelberg J, et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 2000, 287:1809.
22. Davidsen T, Tonjum T Meningococcal genome dynamics. Nat Rev Microbiol 2006, 4:11.
23. Swartley JS, Marfin AA, Edupuganti S, et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA 1997, 94:271.
24. Casadevall A, Pirofski LA Host-pathogen interactions: basic concepts of microbial commensalism, colonization, infection, and disease. Infect Immun 2000, 68:6511.
25. Yazdankhah SP, Caugant DA Neisseria meningitidis: an overview of the carriage state. J Med Microbiol 2004, 53:821.
26. Griffiss JM, Brandt BL, Jarvis GA Natural immunity to Neisseria meningitidis. Evolution of Meningococcal Disease 1987, Vol 2:99. CRC Press, Boca Raton, FL.
27. Teyssou R, Muros-Le Rouzic E Meningitis epidemics in Africa: a brief overview. Vaccine 2007, 25(suppl 1):A3.
28. Wenger JD, Perkins BA Patterns in the emergence of epidemic meningococcal disease. Emerging Infections 1 1998, 125. American Society for Microbiology, Washington, DC. W.M. Scheld, D.A. Armstrong, J.M. Hughes (Eds.).
29. Riedo FX, Plikaytis BD, Broome CV Epidemiology and prevention of meningococcal disease. Pediatr Infect Dis J 1995, 14:643.
30. Olyhoek T, Crowe BA, Achtman M Clonal population structure of Neisseria meningitidis serogroup A isolated from epidemics and pandemics between 1915 and 1983. Rev Infect Dis 1987, 9:665.
31. Serogroup B meningococcal disease - Oregon, 1994. MMWR Morb Mortal Wkly Rep 1995, 44:121.
32. Reeves MW, Perkins BA, Diermeyer M, et al. Epidemic-associated Neisseria meningitidis detected by multilocus enzyme electrophoresis. Emerg Infect Dis 1995, 1:53.
33. Caugant DA, Froholm LO, Bovre K, et al. Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc Natl Acad Sci USA 1986, 83:4927.
34. Fischer M, Perkins BA Neisseria meningitidis serogroup B: emergence of the ET-5 complex. Semin Pediatr Infect Dis 1997, 8:50.
35. Jackson LA, Schuchat A, Reeves MW, et al. Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA 1995, 273:383.
36. Whalen CM, Hockin JC, Ryan A, et al. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1995. Emergence of a virulent clone of Neisseria meningitidis. JAMA 1995, 273:390.
37. Ashton FE, Ryan JA, Borczyk A, et al. Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada. J Clin Microbiol 1991, 29:2489.
38. Snape MD, Pollard AJ Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 2005, 5:21.
39. Wilder-Smith A, Goh KT, Barkham T, et al. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis 2003, 36:679.
40. Mayer LW, Reeves MW, Al-Hamdan N, et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex. J Infect Dis 2002, 185:1596.
41. Decosas J, Koama JB Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. Lancet Infect Dis 2002, 2:763.
42. Harrison LH, Trotter CL, Ramsay ME Global epidemiology of meningococcal disease. Vaccine 2009, 27:B51.
43. Herrick WW Extrameningeal meningococcus infections. Arch Intern Med 1919, 23:409.
44. Emonts M, Hazelzet JA, de Groot R, et al. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect Dis 2003, 3:565.
45. de Souza AL, de Oliveira AC, Romano CC, et al. Interleukin-6 activation in ischemic stroke caused by Neisseria meningitidis serogroup C. Int J Cardiol 2008, 127:e160.
46. Wolfe RE, Birbara C Meningococcal infections at an army training center. Am J Med 1968, 44:243.
47. Sullivan TD, LaScolea LJ Neisseria meningitidis bacteremia in children: Quantitation of bacteremia and spontaneous clinical recovery without antibiotic therapy. Pediatrics 1987, 80:63.
48. Carpenter RR, Petersdorf RG The clinical spectrum of bacterial meningitis. Am J Med 1987, 33:262.
49. Feigin RD, Dodge PR Bacterial meningitis: newer concepts of pathophysiology and neurologic sequelae. Pediatr Clin North Am 1976, 23:541.
50. van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004, 351:1849.
51. van de Beek D, de Gans J, Tunkel AR, et al. Community-acquired bacterial meningitis in adults. N Engl J Med 2006, 354:44.
52. de Souza AL, Sztajnbok J, Seguro AC Cerebellar hemorrhage as an atypical complication of meningococcal meningitis. Int J Infect Dis 2008, 12:558.
53. van de Beek D, Patel R, Wijdicks EF Meningococcal meningitis with brainstem infarction. Arch Neurol 2007, 64:1350.
54. Hoogman M, van de Beek D, Weisfelt M, et al. Cognitive outcome in adults after bacterial meningitis. J Neurol Neurosurg Psychiatry 2007, 78:1092.
55. Borg J, Christie D, Coen PG, et al. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics 2009, 123:e502.
56. Weisfelt M, Determann RM, de Gans J, et al. Procoagulant and fibrinolytic activity in cerebrospinal fluid from adults with bacterial meningitis. J Infect 2007, 54:545.
57. van de Beek D, Weisfelt M, de Gans J, et al. Drug insight: adjunctive therapies in adults with bacterial meningitis. Nat Clin Pract Neurol 2006, 2:504.
58. Van Amersfoort ES, Van Berkel TJ, Kuiper J Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 2003, 16:379.
59. Constantin D, Cordenier A, Robinson K, et al. Neisseria meningitidis-induced death of cerebrovascular endothelium: mechanisms triggering transcriptional activation of inducible nitric oxide synthase. J Neurochem 2004, 89:1166.
60. de Souza AL, Sztajnbok J, Seguro AC Myocardial infarction after meningococcal infection: a potential inflammatory link or a challenging puzzle?. Int J Cardiol 2008, 131:141.
61. Nadel S, Kroll JS Diagnosis and management of meningococcal disease: the need for centralized care. FEMS Microbiol Rev 2007, 31:71.
62. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet 2006, 367:397.
63. de Souza AL, Sztajnbok J, Salgado MM, et al. Severe myalgia of the lower extremities as the first clinical feature of meningococcal purpura fulminans. Am J Trop Med Hyg 2007, 77:723.
64. de Souza AL, Rodrigues C, Sztajnbok J, et al. Hypoelectrolytemia accompanied by acute renal failure in exertional heatstroke. Am J Emerg Med 2006, 24:888.
65. Inkelis SH, O'Leary D, Wang VJ, et al. Extremity pain and refusal to walk in children with invasive meningococcal disease. Pediatrics 2002, 110(1 Pt 1):e3.
66. de Souza AL, Salgado MM, Alkmin MD, et al. Purulent pericarditis caused by Neisseria meningitidis serogroup C and confirmed through polymerase chain reaction. Scand J Infect Dis 2006, 38:143.
67. de Souza AL, Marques Salgado M, Romano CC, et al. Cytokine activation in purulent pericarditis caused by Neisseria meningitidis serogroup C. Int J Cardiol 2006, 113:419.
68. Vienne P, Ducos-Galand M, Guiyoule A, et al. The role of particular strains of Neisseria meningitidis in meningococcal arthritis, pericarditis, and pneumonia. Clin Infect Dis 2007, 37:1639.
69. Bernardini G, Braconi D, Lusini P, et al. Postgenomics of Neisseria meningitidis: an update. Expert Rev Proteomics 2009, 6:135.
70. de Souza AL, Sztajnbok J, Marques Salgado M, et al. Compartmentalization of interleukin-6 response in a patient with septic meningococcal peritonitis. Clin Vaccine Immunol 2006, 13:1287.
71. van Deuren M, Brandtzaeg P Myocardial dysfunction in meningococcal septic shock: no clear answer yet. Crit Care Med 2005, 33:1884.
72. Hardman JM, Earle KM Myocarditis in 200 fatal meningococcal infections. Arch Pathol 1969, 87:318.
73. Pathan N, Hemingway CA, Alizadeh AA, et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet 2004, 363:203.
74. Putsch RW, Hamilton JD, Wolinsky E Neisseria meningitidis, a respiratory pathogen. J Infect Dis 1970, 121:48.
75. Anderson MS, Glodé MP, Smith AL Meningococcal disease. Textbook of Pediatric Infectious Diseases 1998, 1143. WB Saunders, Philadelphia, PA. 4th edn. R.D. Feigin, J.D. Cherry (Eds.).
76. Winstead JM, McKinsey DS, Tasker S, et al. Meningococcal pneumonia: characterization and review of cases seen over the past 25 years. Clin Infect Dis 2000, 30:87.
77. de Souza AL, Seguro AC Conjunctivitis secondary to Neisseria meningitidis: a potential vertical transmission pathway. Clin Pediatr (Phila) 2009, 48:119.
78. Judson FN, Ehret JM, Eickhoff TC Anogenital infection with Neisseria meningitidis in homosexual men. J Infect Dis 1978, 137:458.
79. Janda WM, Bohnoff M, Morello JA, et al. Prevalence and site-pathogen studies of Neisseria meningitidis and N. gonorrhoeae in homosexual men. JAMA 1980, 244:2060.
80. Edwards S, Carne C Oral sex and transmission of non-viral STIs. Sex Transm Infect 1998, 74:95.
81. Parmentier L, Garzoni C, Antille C, et al. Value of a novel Neisseria meningitidis - specific polymerase chain reaction assay in skin biopsy specimens as a diagnostic tool in chronic meningococcemia. Arch Dermatol 2008, 144:770.
82. Rompalo AM, Hood EW, Roberts PL, et al. The acute arthritis dermatitis syndrome. The changing importance of Neisseria gonorrhoeae and Neisseria meningitidis. Arch Intern Med 1987, 147:281.
83. Wehrhahn MC, Heath CH, Leong W A cold case of meningococcal meningitis. Lancet Infect Dis 2009, 9:454.
84. Lo H, Tang CM, Exley RM Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development. Lancet Infect Dis 2009, 9:418.
85. Mathew S, Overturf GD Complement and properidin deficiencies in meningococcal disease. Pediatr Infect Dis J 2006, 25:255.
86. Overturf GD Indications for the immunological evaluation of patients with meningitis. Clin Infect Dis 2003, 36:189.
87. Smith AL Neonatal bacterial meningitis. Infections of the Central Nervous System 1997, 313. Lippincott-Raven, Philadelphia. 2nd edn. W.M. Scheld, R.J. Whitley, D.T. Durack (Eds.).
88. Goldschneider I, Gotschlich EC, Artenstein MS Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969, 129:1307.
89. Fijen CA, Kuijper EJ, Tjia HG, et al. Complement deficiency predisposes for meningitis due to nongroupable meningococci and Neisseria-related bacteria. Clin Infect Dis 1994, 18:780.
90. Sjoholm AG, Kuijper EJ, Tijsen CC, et al. Dysfunctional properdin in a Dutch family with meningococcal disease. N Engl J Med 1988, 319:33.
91. Hubert B, Watier L, Garnerin P, et al. Meningococcal disease and influenza-like syndrome: a new approach to an old question. J Infect Dis 1992, 166:542.
92. Moore PS, Hierholzer J, De Witt W, et al. Respiratory viruses and mycoplasma as cofactors for epidemic group A meningococcal meningitis. JAMA 1990, 264:1271.
93. Carbonnelle E, Hill DJ, Morand P, et al. Meningococcal interactions with the host. Vaccine 2009, 27(suppl 2):B78.
94. Rayner CFJ, Dewar A, Moxon ER, et al. The effect of variations in the expression of pili on the interaction of Neisseria meningitidis with human nasopharyngeal epithelium. J Infect Dis 1995, 171:113.
95. Virji M, Makepeace M, Ferguson DJ, et al. Carcinoembryonic antigens (CD66) on epithelial cells and neutrophils are receptors for Opa proteins of pathogenic neisseriae. Mol Microbiol 1996, 22:941.
96. Stephens DS, Greenwood B, Brandtzaeg P Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007, 369:2196.
97. Beutler B, Rietschel ET Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 2003, 3:169.
98. Palsson-McDermott EM, O'Neill LA Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology 2004, 113:153.
99. Fransen F, Heckenberg SG, Hamstra HJ, et al. Naturally occurring lipid A mutants in Neisseria meningitidis from patients with invasive meningococcal disease are associated with reduced coagulopathy. PLoS Pathog 2009, 5. e1000396.
100. Wispelwey B, Hansen EJ, Scheld WM Haemophilus influenzae outer membrane vesicle induced blood-brain barrier permeability during experimental meningitis in the rat. J Clin Invest 1988, 82:1339.
101. Levin S, Painter MB The treatment of acute meningococcal infection in adults. Ann Intern Med 1966, 64:1049.
102. Feldman WE Relation of concentrations of bacteria and bacterial antigen in cerebrospinal fluid to prognosis in patients with bacterial meningitis. N Engl J Med 1977, 296:433.
103. Feldman WE Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis. J Pediatr 1976, 88:549.
104. McCracken GH Rapid identification of specific etiology in meningitis. J Pediatr 1976, 88:706.
105. Ni H, Knight AI, Cartwright K, et al. Polymerase chain reaction for diagnosis of meningococcal meningitis. Lancet 1993, 340:1432.
106. Seward RJ, Towner KJ Evaluation of a PCR-immunoassay technique for detection of Neisseria meningitidis in cerebrospinal fluid and peripheral blood. J Med Microbiol 2000, 49:451.
107. Diggle MA, Clarke SC Detection and genotyping of meningococci using a nested PCR approach. J Med Microbiol 2003, 52:51.
108. Saravolatz LD, Manzor O, VanderVelde N, et al. Broad-range bacterial polymerase chain reaction for early detection of bacterial meningitis. Clin Infect Dis 2003, 36:40.
109. Van Esso D, Fontanals D, Uriz S, et al. Neisseria meningitidis strains with decreased susceptibility to penicillin. Pediatr Infect Dis 1987, 6:438.
110. Saez-Nieto JA, Lujan R, Berron S, et al. Epidemiology and molecular basis of penicillin-resistant Neisseria meningitidis in Spain: a 5-year history (1985-1989). Clin Infect Dis 1992, 14:394.
111. Woods CR, Smith AL, Wasilauskas BL, et al. Invasive disease caused by Neisseria meningitidis relatively resistant to penicillin in North Carolina. J Infect Dis 1994, 170:453.
112. Jackson LA, Tenover FC, Baker C, et al. Prevalence of Neisseria meningitidis relatively resistant to penicillin in the United States, 1991. J Infect Dis 1994, 169:438.
113. Fitch MT, van de Beek D Drug insight: steroids in CNS infectious diseases - new indications for an old therapy. Nat Clin Pract Neurol 2008, 4:97.
114. Peltola H, Roine I, Fernández J, et al. Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis: a prospective, randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2007, 45:1277.
115. Leclerc F, Leteurtre S, Cremer R, et al. Do new strategies in meningococcemia produce better outcomes?. Crit Care Med 2000, 28(9 suppl):S60.
116. Cartwright K, Reilly S, White D, et al. Early treatment with parenteral penicillin in meningococcal disease. BMJ 1992, 305:143.
117. Strang JR, Pugh EJ Meningococcal infections: reducing the case fatality rate by giving penicillin before admission to hospital. BMJ 1992, 305:141.
118. Purcell B, Samuelsson S, Hahné SJ, et al. Effectiveness of antibiotics in preventing meningococcal disease after a case: systematic review. BMJ 2004, 328:1339.
119. Guttler RB, Counts GW, Avent CK, et al. Effect of rifampin and minocycline on meningococcal carrier rates. J Infect Dis 1971, 124:199.
120. Weidner CE, Dunkel TB, Pettyjohn FS, et al. Effectiveness of rifampin in eradicating the meningococcal carrier state in a relatively closed population: emergence of resistant strains. J Infect Dis 1971, 124:172.
121. Girgis N, Sultan Y, Frenck RW, et al. Azithromycin compared with rifampin for eradication of nasopharyngeal colonization by Neisseria meningitidis. Pediatr Infect Dis J 1998, 17:816.
122. Gilja HO, Halstensen A, Digranes A, et al. Single-dose ofloxacin to eradicate tonsillopharyngeal carriage of Neisseria meningitidis. Antimicrob Agents Chemother 1993, 37:2024.
123. Pugsley MP, Dworzack DI, Horowitz EA, et al. Efficacy of ciprofloxacin in treatment of nasopharyngeal carriers of Neisseria meningitidis. J Infect Dis 1987, 156:211.
124. The Meningococcal Disease Surveillance Group Analysis of endemic meningococcal disease by serogroup and evaluation of chemoprophylaxis. J Infect Dis 1976, 134:201.
125. Artenstein MS, Ellis RE The risk of exposure to a patient with meningococcal meningitis. Mil Med 1968, 133:474.
126. Twumasi PAJ, Kumah S, Leach A, et al. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 1995, 171:632.
127. Lieberman JM, Chiu SS, Wong VK, et al. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. JAMA 1996, 275:1499.
128. Fairley CK, Begg N, Borrow R, et al. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J Infect Dis 1996, 174:1360.
129. Leach A, Twumasi PA, Kumah S, et al. Induction of immunologic memory of Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis 1997, 175:200.
130. Soriano-Gabarro M, Stuart JM, Rosenstein NE Vaccines for the prevention of meningococcal disease in children. Semin Pediatr Infect Dis 2002, 13:182.
131. Ramsay ME, Andrews N, Kaczmarski EB, et al. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001, 357:195.
132. Maiden MC, Stuart JM Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002, 359:1829. The UK meningococcal carriage group.
133. Ramsay ME, Andrews NJ, Trotter CL, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003, 326:365.
134. Menactra: a meningococcal conjugate vaccine. Med Lett Drugs Ther 2005, 47:29.
135. Brigham KS, Sandora TJ Neisseria meningitidis: epidemiology, treatment and prevention in adolescents. Curr Opin Pediatr 2009, 21:437.
136. Pichichero M, Casey J, Blatter M, et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J 2005, 24:57.
137. Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11-18 years with meningococcal conjugate vaccine. MMWR Morb Mortal Wkly Rep 2007, 56:794.
138. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC) Report from the Advisory Committee on Immunization Practices (ACIP): decision not to recommend routine vaccination of all children aged 2-10 years with quadrivalent meningococcal conjugate vaccine (MCV4). MMWR Morb Mortal Wkly Rep 2008, 57:462.
139. LaForce MF, Ravenscroft N, Djingarey M, et al. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009, 27(suppl 2):B13.